- Home
- SOPH vs DSGN Comparison
SOPH vs DSGN Comparison
Compare SOPH & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- DSGN
- Stock Information
- Founded
- SOPH 2011
- DSGN 2017
- Country
- SOPH Switzerland
- DSGN United States
- Employees
- SOPH N/A
- DSGN N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- DSGN Health Care
- Exchange
- SOPH Nasdaq
- DSGN Nasdaq
- Market Cap
- SOPH 193.8M
- DSGN 224.8M
- IPO Year
- SOPH 2021
- DSGN 2021
- Fundamental
- Price
- SOPH $3.04
- DSGN $3.71
- Analyst Decision
- SOPH Strong Buy
- DSGN Hold
- Analyst Count
- SOPH 2
- DSGN 1
- Target Price
- SOPH $6.50
- DSGN $4.00
- AVG Volume (30 Days)
- SOPH 162.8K
- DSGN 93.8K
- Earning Date
- SOPH 08-05-2025
- DSGN 08-04-2025
- Dividend Yield
- SOPH N/A
- DSGN N/A
- EPS Growth
- SOPH N/A
- DSGN N/A
- EPS
- SOPH N/A
- DSGN N/A
- Revenue
- SOPH $67,173,000.00
- DSGN N/A
- Revenue This Year
- SOPH $16.07
- DSGN N/A
- Revenue Next Year
- SOPH $22.94
- DSGN N/A
- P/E Ratio
- SOPH N/A
- DSGN N/A
- Revenue Growth
- SOPH 4.66
- DSGN N/A
- 52 Week Low
- SOPH $2.58
- DSGN $2.60
- 52 Week High
- SOPH $5.00
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- SOPH 53.60
- DSGN 47.78
- Support Level
- SOPH $2.80
- DSGN $3.66
- Resistance Level
- SOPH $3.08
- DSGN $3.84
- Average True Range (ATR)
- SOPH 0.23
- DSGN 0.25
- MACD
- SOPH 0.01
- DSGN -0.02
- Stochastic Oscillator
- SOPH 61.64
- DSGN 18.06
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.